title: Infarct size reduction: a review of clinical trials.
abstract: Early studies in experimental animals and in humans indicated the need to examine the feasibility of infarct size reduction by the early treatment of patients recruited to well-designed clinical trials. The extensive experience with beta-adrenoceptor blockers and the comparatively recent data generated with the use of calcium antagonists in patients with acute myocardial infarction are reviewed. Early intravenous administration of beta-adrenoceptor blockers in suitable patients appears to produce genuine infarct size reduction (approximately 20%) compared with controls, whereas calcium channel antagonists have failed to demonstrate such an effect. Possible mechanisms for these findings are discussed.
authors: Medical Research Department, ICI Pharmaceuticals, Cheshire, England.
authors: T J
authors: TJ
authors: Fitzsimons
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000517:prevention & control
chemical_list: D000319:Adrenergic beta-Antagonists; D002121:Calcium Channel Blockers